We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF
PBE

69 hedge funds and large institutions have $52.3M invested in Invesco Biotechnology & Genome ETF in 2017 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 4

15% more funds holding

Funds holding: 60 → 69 (+9)

1.14% more ownership

Funds ownership: 21.02% → 22.16% (+1.1%)

5% less capital invested

Capital invested by funds: $55M → $52.3M (-$2.71M)

13% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 16

Holders
69
Holders Change
+9
Holders Change %
+15%
% of All Funds
1.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
14
Reduced
16
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$2.11M
2
Citadel Advisors
Citadel Advisors
Florida
+$398K
3
LTFS
Ladenburg Thalmann Financial Services
Florida
+$316K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$230K
5
BTS
BB&T Securities
Virginia
+$225K

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$1.71M
2
RJFSA
Raymond James Financial Services Advisors
Florida
-$544K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$522K
4
Goldman Sachs
Goldman Sachs
New York
-$256K
5
TSS
Two Sigma Securities
New York
-$226K
Name Holding Trade Value Shares
Change 		Change in
Stake
SAM
26
SignalPoint Asset Management
Missouri
$431K – – –
Citadel Advisors
27
Citadel Advisors
Florida
$400K +$398K +8,485 New
FHA
28
Flagship Harbor Advisors
Massachusetts
$393K – – –
Janney Montgomery Scott
29
Janney Montgomery Scott
Pennsylvania
$379K -$90K -1,920 -19%
GT
30
Glenview Trust
Kentucky
$361K – – –
Jane Street
31
Jane Street
New York
$339K +$96.7K +2,064 +40%
TAM
32
Trillium Asset Management
Massachusetts
$320K -$5.95K -127 -2%
JIC
33
Joel Isaacson & Co
New York
$317K – – –
AG
34
Advisor Group
Arizona
$311K -$129K -2,754 -29%
BRF
35
B. Riley Financial
California
$288K – – –
MML Investors Services
36
MML Investors Services
Massachusetts
$276K -$75.5K -1,610 -22%
WB
37
Webster Bank
Connecticut
$254K – – –
CIC
38
Carnegie Investment Counsel
Ohio
$245K – – –
BTS
39
BB&T Securities
Virginia
$226K +$225K +4,797 New
UCFA
40
United Capital Financial Advisors
Texas
$213K +$212K +4,526 New
Citigroup
41
Citigroup
New York
$198K +$11.7K +250 +6%
CIBC Private Wealth Group
42
CIBC Private Wealth Group
Georgia
$138K +$137K +2,925 New
IA
43
IFP Advisors
Florida
$135K +$7.26K +155 +6%
KFA
44
Kabarec Financial Advisors
Illinois
$131K +$130K +2,780 New
Envestnet Asset Management
45
Envestnet Asset Management
Illinois
$127K +$3.38K +72 +3%
GT
46
Glenmede Trust
Pennsylvania
$74K – – –
JCM
47
Jacobi Capital Management
Pennsylvania
$58K – – –
SWP
48
Stratos Wealth Partners
Ohio
$48K +$47.3K +1,009 New
SEI Investments
49
SEI Investments
Pennsylvania
$44K – – –
LF
50
Lee Financial
Texas
$37K – – –
1
2
3

PBE Hedge Fund Activity: Q4 2017 in Review

69 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q4 2017, worth a combined $52.3M — down 4.9% from $55M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new PBE positions and 4 closed out — a net gain of 9 holders — while 14 added to existing stakes and 16 trimmed.

The largest buyer was Virtu Financial, adding an estimated $2.11M. The largest seller was Bank of America, cutting an estimated $1.71M.

  • 69 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q4 2017, up from 60 in Q3 2017.
  • Funds reported $52.3M of Invesco Biotechnology & Genome ETF stock for Q4 2017, down 4.9% quarter-over-quarter.
  • 13 funds opened new Invesco Biotechnology & Genome ETF positions in Q4 2017 and 4 closed out, a net change of +9 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q4 2017 was Virtu Financial, an estimated $2.11M added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q4 2017 was Bank of America, an estimated $1.71M sold.

Based on aggregated 13F filings for Q4 2017.